{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T10:35:01Z","timestamp":1785234901981,"version":"3.55.0"},"reference-count":92,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2020,10,16]],"date-time":"2020-10-16T00:00:00Z","timestamp":1602806400000},"content-version":"unspecified","delay-in-days":15,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2020,9,10]]},"published-print":{"date-parts":[[2020,10]]},"abstract":"<jats:p>In the evolving immune-oncology landscape, numerous patients with cancer are constantly treated with immune checkpoint inhibitors (ICPIs) but among them, only sporadic cases with pre-existing hepatitis B virus (HBV) and hepatitis C virus (HCV) are recorded. Despite the global dissemination of HBV and HCV infections, viral hepatitis-infected patients with cancer were traditionally excluded from ICPIs containing trials and current evidence is particularly limited in case reports, retrospective cohort studies and in few clinical trials on advanced hepatocellular carcinoma. Thus, many concerns still remain about the overall oncological management of this special subpopulation, including questions about the efficacy, toxicity and reactivation risks induced by ICPIs. Here, we examine the natural course of both HBV and HCV in cancer environment, review the latest antiviral guidelines for patients undergoing systematic cancer therapies, estimating treatment-related immunosuppression and relocate immunotherapy in this therapeutic panel. Among the ICPIs-treated cases with prior viral hepatitis, we focus further on those experienced HBV or HCV reactivation and discuss their host, tumor and serological risk factors, their antiviral and immunological management as well as their hepatitis and tumor outcome. Based on a low level of evidence, immunotherapy in these specific cancer cases seems to be associated with no inferior efficacy and with a relevantly low reactivation rate. However, hepatitis reactivation and subsequent irreversible complications appeared to have poor response to deferred antiviral treatment. While, the prophylactic use of modern antiviral drugs could eliminate or diminish up front the viral load in most cases, leading to cure or long-term hepatitis control. Taking together the clinical significance of preventive therapy, the low but existing reactivation risk and the potential immune-related hepatotoxicity, a comprehensive baseline assessment of liver status, including viral hepatitis screening, before the onset of immunotherapy should be suggested as a reasonable and maybe cost-effective strategy but the decision to administer ICPIs and the necessity of prophylaxis should always be weighed at a multidisciplinary level and be individualized in each case, up to be established by future clinical trials.<\/jats:p>","DOI":"10.1136\/jitc-2020-000943","type":"journal-article","created":{"date-parts":[[2020,10,16]],"date-time":"2020-10-16T17:45:18Z","timestamp":1602870318000},"page":"e000943","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":32,"title":["Reconsidering the management of patients with cancer with viral hepatitis in the era of immunotherapy"],"prefix":"10.1136","volume":"8","author":[{"given":"Dimitrios C","family":"Ziogas","sequence":"first","affiliation":[{"name":"First Department of Medicine, National and Kapodistrian University of Athens School of Medicine, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frosso","family":"Kostantinou","sequence":"additional","affiliation":[{"name":"First Department of Medicine, National and Kapodistrian University of Athens School of Medicine, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelos","family":"Cholongitas","sequence":"additional","affiliation":[{"name":"First Department of Medicine, National and Kapodistrian University of Athens School of Medicine, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amalia","family":"Anastasopoulou","sequence":"additional","affiliation":[{"name":"First Department of Medicine, National and Kapodistrian University of Athens School of Medicine, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiotis","family":"Diamantopoulos","sequence":"additional","affiliation":[{"name":"First Department of Medicine, National and Kapodistrian University of Athens School of Medicine, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Haanen","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Gogas","sequence":"additional","affiliation":[{"name":"First Department of Medicine, National and Kapodistrian University of Athens School of Medicine, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,10,16]]},"reference":[{"key":"2025100309505703000_8.2.e000943.1","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-019-0116-x"},{"key":"2025100309505703000_8.2.e000943.2","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1001\/jamaoncol.2018.6437","article-title":"Prevalence of hepatitis B virus, hepatitis C virus, and HIV infection among patients with newly diagnosed cancer from academic and community oncology practices","volume":"5","author":"Ramsey","year":"2019","journal-title":"JAMA Oncol"},{"key":"2025100309505703000_8.2.e000943.3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)61412-X"},{"key":"2025100309505703000_8.2.e000943.4","doi-asserted-by":"publisher","DOI":"10.7326\/M13-1133"},{"key":"2025100309505703000_8.2.e000943.5","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1097\/QAD.0000000000001599","article-title":"Hepatitis B reactivation in a long-term nonprogressor due to nivolumab therapy","volume":"31","author":"Lake","year":"2017","journal-title":"AIDS"},{"key":"2025100309505703000_8.2.e000943.6","first-page":"1","article-title":"A rare case of pembrolizumab-induced reactivation of hepatitis B","volume":"2018","author":"Pandey","year":"2018","journal-title":"Case Rep Oncol Med"},{"key":"2025100309505703000_8.2.e000943.7","doi-asserted-by":"crossref","first-page":"3103","DOI":"10.1093\/annonc\/mdx502","article-title":"Hbv-related acute hepatitis due to immune checkpoint inhibitors in a patient with malignant melanoma","volume":"28","author":"Koksal","year":"2017","journal-title":"Ann Oncol"},{"key":"2025100309505703000_8.2.e000943.8","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1177\/1078155219882071","article-title":"Safe use of nivolumab in a patient with renal cell carcinoma and hepatitis B","volume":"26","author":"Akar","year":"2020","journal-title":"J Oncol Pharm Pract"},{"key":"2025100309505703000_8.2.e000943.9","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0808-5"},{"key":"2025100309505703000_8.2.e000943.10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31046-2"},{"key":"2025100309505703000_8.2.e000943.11","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30351-6"},{"key":"2025100309505703000_8.2.e000943.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2013.02.022"},{"key":"2025100309505703000_8.2.e000943.13","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0316-z"},{"key":"2025100309505703000_8.2.e000943.14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.6385"},{"key":"2025100309505703000_8.2.e000943.15","doi-asserted-by":"crossref","first-page":"3745","DOI":"10.1200\/JCO.2017.73.4186","article-title":"Re-evaluating eligibility criteria for oncology clinical trials: analysis of investigational new drug applications in 2015","volume":"35","author":"Jin","year":"2017","journal-title":"J Clin Oncol"},{"key":"2025100309505703000_8.2.e000943.16","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0717-7"},{"key":"2025100309505703000_8.2.e000943.17","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1200\/JOP.19.00370","article-title":"Oncologic implications of chronic hepatitis C virus infection","volume":"15","author":"Hwang","year":"2019","journal-title":"J Oncol Pract"},{"key":"2025100309505703000_8.2.e000943.18","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1056\/NEJMra1810477","article-title":"Global elimination of chronic hepatitis","volume":"380","author":"Thomas","year":"2019","journal-title":"N Engl J Med"},{"key":"2025100309505703000_8.2.e000943.19","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02844-06"},{"key":"2025100309505703000_8.2.e000943.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2007.07.038"},{"key":"2025100309505703000_8.2.e000943.21","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2013.12.036"},{"key":"2025100309505703000_8.2.e000943.22","doi-asserted-by":"publisher","DOI":"10.1172\/JCI36604"},{"key":"2025100309505703000_8.2.e000943.23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0063818"},{"key":"2025100309505703000_8.2.e000943.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2006.05.013"},{"key":"2025100309505703000_8.2.e000943.25","first-page":"411","article-title":"The oncologic burden of hepatitis C virus infection: a clinical perspective","volume":"67","author":"Torres","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"2025100309505703000_8.2.e000943.26","doi-asserted-by":"crossref","DOI":"10.3390\/jcm8122085","article-title":"Correlation between hepatitis B virus infection and colorectal neoplasia","volume":"8","author":"Jung","year":"2019","journal-title":"J Clin Med"},{"key":"2025100309505703000_8.2.e000943.27","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djw035","article-title":"Association between hepatitis C virus and head and neck cancers","volume":"108","author":"Mahale","year":"2016","journal-title":"J Natl Cancer Inst"},{"key":"2025100309505703000_8.2.e000943.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.cld.2017.03.009"},{"key":"2025100309505703000_8.2.e000943.29","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1053\/j.gastro.2017.02.009","article-title":"Hepatitis B reactivation associated with immune suppressive and biological modifier therapies: current concepts, management strategies, and future directions","volume":"152","author":"Loomba","year":"2017","journal-title":"Gastroenterology"},{"key":"2025100309505703000_8.2.e000943.30","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.cgh.2016.06.008","article-title":"Hbv-associated acute liver failure after immunosuppression and risk of death","volume":"15","author":"Karvellas","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025100309505703000_8.2.e000943.31","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21051"},{"key":"2025100309505703000_8.2.e000943.32","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29800"},{"key":"2025100309505703000_8.2.e000943.33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.03.021"},{"key":"2025100309505703000_8.2.e000943.34","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-015-9675-4"},{"key":"2025100309505703000_8.2.e000943.35","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1002\/phar.2340","article-title":"Hepatitis B virus reactivation: risk factors and current management strategies","volume":"39","author":"Smalls","year":"2019","journal-title":"Pharmacotherapy"},{"key":"2025100309505703000_8.2.e000943.36","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29344"},{"key":"2025100309505703000_8.2.e000943.37","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/liv.14282","article-title":"Securing sustainable funding for viral hepatitis elimination plans","volume":"40","author":"Hatzakis","year":"2020","journal-title":"Liver Int"},{"key":"2025100309505703000_8.2.e000943.38","unstructured":"Centers for disease control and prevention . Hepatitis risk assessment. Available: Https:\/\/www.Cdc.Gov\/hepatitis\/riskassessment\/index.Htm [Accessed 1 Mar 2018]."},{"key":"2025100309505703000_8.2.e000943.39","doi-asserted-by":"publisher","DOI":"10.1086\/653622"},{"key":"2025100309505703000_8.2.e000943.40","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-154-5-201103010-00006"},{"key":"2025100309505703000_8.2.e000943.41","unstructured":"Centers for Disease Control and Prevention . Viral hepatitis surveillance us, 2015. Available: https:\/\/www.cdc.gov\/hepatitis\/statistics\/2015surveillance\/pdfs\/2015hepsurveillancerpt.pdf [Accessed 22 Mar 2018]."},{"key":"2025100309505703000_8.2.e000943.42","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6601699"},{"key":"2025100309505703000_8.2.e000943.43","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2016.0024"},{"key":"2025100309505703000_8.2.e000943.44","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1111\/jvh.12402","article-title":"Hepatitis B reactivation in HBsAg-negative\/HBcAb-positive patients receiving rituximab for lymphoma: a meta-analysis","volume":"22","author":"Mozessohn","year":"2015","journal-title":"J Viral Hepat"},{"key":"2025100309505703000_8.2.e000943.45","doi-asserted-by":"publisher","DOI":"10.1055\/s-0033-1345722"},{"key":"2025100309505703000_8.2.e000943.46","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/S2468-1253(18)30002-5","article-title":"Hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C: a systematic review and meta-analysis","volume":"3","author":"M\u00fccke","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025100309505703000_8.2.e000943.47","doi-asserted-by":"publisher","DOI":"10.1002\/1096-9071(200011)62:3<299::AID-JMV1>3.0.CO;2-0"},{"key":"2025100309505703000_8.2.e000943.48","doi-asserted-by":"publisher","DOI":"10.1097\/00004836-199010000-00015"},{"key":"2025100309505703000_8.2.e000943.49","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2003.09.026"},{"key":"2025100309505703000_8.2.e000943.50","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.48.5938"},{"key":"2025100309505703000_8.2.e000943.51","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v21.i36.10274"},{"key":"2025100309505703000_8.2.e000943.52","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.12154"},{"key":"2025100309505703000_8.2.e000943.53","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.10.039"},{"key":"2025100309505703000_8.2.e000943.54","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1053\/j.gastro.2014.10.038","article-title":"American gastroenterological association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy","volume":"148","author":"Perrillo","year":"2015","journal-title":"Gastroenterology"},{"key":"2025100309505703000_8.2.e000943.55","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw414"},{"key":"2025100309505703000_8.2.e000943.56","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0132426","article-title":"Risk of severe acute exacerbation of chronic HBV infection cancer patients who underwent chemotherapy and did not receive anti-viral prophylaxis","volume":"10","author":"Shih","year":"2015","journal-title":"PLoS One"},{"key":"2025100309505703000_8.2.e000943.57","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104765","article-title":"Role of hepatitis B antibody in predicting reactivation of resolved hepatitis B virus infection in leukemia patients","volume":"177","author":"Wu","year":"2020","journal-title":"Antiviral Res"},{"key":"2025100309505703000_8.2.e000943.58","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/CMR.0000000000000434","article-title":"Safety and efficacy of anti-PD-1 therapy for metastatic melanoma and non-small-cell lung cancer in patients with viral hepatitis: a case series","volume":"28","author":"Kothapalli","year":"2018","journal-title":"Melanoma Res"},{"key":"2025100309505703000_8.2.e000943.59","first-page":"1","article-title":"Pd-1 blockade in advanced melanoma in patients with hepatitis C and\/or HIV","volume":"2015","author":"Davar","year":"2015","journal-title":"Case Rep Oncol Med"},{"key":"2025100309505703000_8.2.e000943.60","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ejca.2018.09.017","article-title":"Anti-PD-1\/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B\/C infection","volume":"104","author":"Tio","year":"2018","journal-title":"Eur J Cancer"},{"key":"2025100309505703000_8.2.e000943.61","unstructured":"Lok ASF MB . AASLD practice guideline update: chronic hepatitis B, 2009. Available: Http:\/\/www.Aasld.Org\/sites\/default\/files\/guideline_documents\/ chronichepatitisb2009.Pdf."},{"key":"2025100309505703000_8.2.e000943.62","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.61.3745"},{"key":"2025100309505703000_8.2.e000943.63","first-page":"480","article-title":"Hepatitis B virus reactivation in HBsAg-negative, anti-HBc-positive patients receiving immunosuppressive therapy: a systematic review","volume":"31","author":"Cholongitas","year":"2018","journal-title":"Ann Gastroenterol"},{"key":"2025100309505703000_8.2.e000943.64","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.jcv.2012.07.015","article-title":"Significant rate of hepatitis B reactivation following kidney transplantation in patients with resolved infection","volume":"55","author":"Kanaan","year":"2012","journal-title":"J Clin Virol"},{"key":"2025100309505703000_8.2.e000943.65","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2009.05.001"},{"key":"2025100309505703000_8.2.e000943.66","doi-asserted-by":"crossref","first-page":"30642","DOI":"10.18632\/oncotarget.8907","article-title":"Systematic review with network meta-analysis: Comparative efficacy of oral nucleos(t)ide analogues for the prevention of chemotherapy-induced hepatitis B virus reactivation","volume":"7","author":"Zhang","year":"2016","journal-title":"Oncotarget"},{"key":"2025100309505703000_8.2.e000943.67","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21024"},{"key":"2025100309505703000_8.2.e000943.68","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22106"},{"key":"2025100309505703000_8.2.e000943.69","unstructured":"NICE . National Institute for health and care excellence: hepatitis B (chronic): diagnosis and management of chronic hepatitis B in children, young people, and adults. Available: http:\/\/www.Nice.Org.Uk\/guidance\/cg165"},{"key":"2025100309505703000_8.2.e000943.70","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.15704"},{"key":"2025100309505703000_8.2.e000943.71","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.3109\/10428194.2015.1116121","article-title":"Hepatitis B virus reactivation after withdrawal of prophylactic antiviral therapy in patients with diffuse large B cell lymphoma","volume":"57","author":"Liu","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"2025100309505703000_8.2.e000943.72","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.leukres.2016.09.014","article-title":"Delayed HBV reactivation in rituximab-containing chemotherapy: how long should we continue anti-virus prophylaxis or monitoring HBV-DNA?","volume":"50","author":"Nakaya","year":"2016","journal-title":"Leuk Res"},{"key":"2025100309505703000_8.2.e000943.73","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(16)00118-3"},{"key":"2025100309505703000_8.2.e000943.74","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.07.033"},{"key":"2025100309505703000_8.2.e000943.75","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.2013.001215"},{"key":"2025100309505703000_8.2.e000943.76","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22759"},{"key":"2025100309505703000_8.2.e000943.77","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1053\/j.gastro.2019.01.271","article-title":"Hepatitis C virus infection in patients with cancer: impact on clinical trial enrollment, selection of therapy, and prognosis","volume":"157","author":"Torres","year":"2019","journal-title":"Gastroenterology"},{"key":"2025100309505703000_8.2.e000943.78","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.16095"},{"key":"2025100309505703000_8.2.e000943.79","unstructured":"AASLD-IDSA . Hcv guidance: recommendations for testing, managing, and treating hepatitis C. Available: www.Hcvguidelines.Org [Accessed 6 Nov 2019]."},{"key":"2025100309505703000_8.2.e000943.80","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-05-718643"},{"key":"2025100309505703000_8.2.e000943.81","doi-asserted-by":"publisher","DOI":"10.1038\/s41395-018-0383-2"},{"key":"2025100309505703000_8.2.e000943.82","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29364"},{"key":"2025100309505703000_8.2.e000943.83","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-05-714667"},{"key":"2025100309505703000_8.2.e000943.84","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1053\/j.gastro.2017.06.012","article-title":"Risk of hepatocellular cancer in HCV patients treated with direct-acting antiviral agents","volume":"153","author":"Kanwal","year":"2017","journal-title":"Gastroenterology"},{"key":"2025100309505703000_8.2.e000943.85","article-title":"HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma","author":"Ioannou","year":"2017","journal-title":"J Hepatol"},{"key":"2025100309505703000_8.2.e000943.86","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1111\/liv.14119","article-title":"Hepatitis C virus infection and non-hepatocellular malignancies in the DAA era: a systematic review and meta-analysis","volume":"39","author":"Masarone","year":"2019","journal-title":"Liver Int"},{"key":"2025100309505703000_8.2.e000943.87","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1111\/apt.13825","article-title":"Concomitant use of direct-acting antivirals and chemotherapy in hepatitis C virus-infected patients with cancer","volume":"44","author":"Economides","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"2025100309505703000_8.2.e000943.88","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0174"},{"key":"2025100309505703000_8.2.e000943.89","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy162"},{"key":"2025100309505703000_8.2.e000943.90","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1093\/cid\/ciy098","article-title":"Population-level outcomes and cost-effectiveness of expanding the recommendation for age-based hepatitis C testing in the United States","volume":"67","author":"Barocas","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2025100309505703000_8.2.e000943.91","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1200\/JCO.18.00374","article-title":"Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: Asco and idsa clinical practice guideline update","volume":"36","author":"Taplitz","year":"2018","journal-title":"JCO"},{"key":"2025100309505703000_8.2.e000943.92","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/apt.14382","article-title":"Direct medical costs associated with the extrahepatic manifestations of hepatitis C virus infection in France","volume":"47","author":"Cacoub","year":"2018","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2020-000943","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T16:51:09Z","timestamp":1759510269000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2020-000943"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":92,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,10,16]]},"published-print":{"date-parts":[[2020,10]]}},"alternative-id":["10.1136\/jitc-2020-000943"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2020-000943","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10]]}}}